---
document_datetime: 2023-12-22 12:01:06
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/dimethyl-fumarate-polpharma-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: dimethyl-fumarate-polpharma-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6303711
conversion_datetime: 2025-12-18 22:19:35.017008
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Dimethyl fumarate Polpharma

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IA/0008              | B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure | 20/09/2023                                  | n/a                                         |                                  |           |
| N/0007               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)     | 30/06/2023                                  |                                             | PL                               |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions

are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0006     | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                     | 13/01/2023   | SmPC                   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------------------|
| IB/0005     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                  | 18/10/2022   | SmPC and PL authorised |
| IAIN/0004   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                            | 26/08/2022   | n/a longer             |
| IAIN/0003/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site | 27/07/2022   | n/a product no         |
| IA/0002/G   | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor Medicinal                                                                                                                                                                                                                                    | 01/07/2022   | n/a                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->